• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Devlin Jodi

    8/31/23 9:04:03 PM ET
    $MTAC
    Medical Specialities
    Health Care
    Get the next $MTAC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Devlin Jodi

    (Last) (First) (Middle)
    6272 W. 91ST AVE.

    (Street)
    WESTMINSTER CO 80031

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    TriSalus Life Sciences, Inc. [ TLSI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    President, Therapeutics
    3. Date of Earliest Transaction (Month/Day/Year)
    08/30/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (right to buy) $6.7 08/30/2023 A 195,000 (1) 08/29/2033 Common Stock 195,000 $0.00 195,000 D
    Explanation of Responses:
    1. One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of August 28, 2023, and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the vesting commencement date.
    Remarks:
    /s/ Mary Szela, Attorney-in-Fact for Jodi Devlin 08/31/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MTAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Szela Mary T was granted 84,899 shares, increasing direct ownership by 30% to 364,862 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:44:45 PM ET
    $MTAC
    Medical Specialities
    Health Care

    Marshak Richard was granted 14,752 shares, increasing direct ownership by 118% to 27,251 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:42:18 PM ET
    $MTAC
    Medical Specialities
    Health Care

    Cox Bryan F. was granted 14,752 shares, increasing direct ownership by 21% to 86,696 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:39:58 PM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

    Advances TriSalus' Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma Provides Cash Runway through Mid-2024 to Fund Key Milestones TriSalus' Common Stock Expected to Begin Trading on the Nasdaq under Symbol "TLSI" on August 11, 2023 TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tu

    8/10/23 4:05:00 PM ET
    $MTAC
    Medical Specialities
    Health Care

    MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders

    MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or the "Company") today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting is being held to vote on certain proposals related to the proposed business combination (the "Business Combination") with TriSalus Life Sciences ("TriSalus"). The Special Meeting has been adjourned until 11:00 a.m. Eastern Time on August 8, 2023. The Special Meeting will still be held virtually via webcast, and stockholders may attend and participate online by visiting https://www.cstproxy.com/medtechacquisition/sm2023. Participants will be able to li

    8/2/23 5:00:00 PM ET
    $MTAC
    Medical Specialities
    Health Care

    TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

    New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company in the process of going public through a business combination transaction (the Business Combination) with MedTech Acquisition Corporation (NASDAQ:MTAC) (MedTech or MTAC), today announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023. TriSalus' ongoing Phase 1 Pressure-Enabled Regional Immuno-Oncology (PERIO-01) (NCT04935229) cl

    6/12/23 7:00:00 AM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    SEC Filings

    View All

    SEC Form 424B3 filed by MedTech Acquisition Corporation

    424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:23:14 PM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form 424B3 filed by MedTech Acquisition Corporation

    424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:21:58 PM ET
    $MTAC
    Medical Specialities
    Health Care

    MedTech Acquisition Corporation filed SEC Form 8-K: Leadership Update

    8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:19:33 PM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Leadership Updates

    Live Leadership Updates

    View All

    TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

    TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced that James "Jim" Alecxih has joined the Company in the newly created role of President, Device Technology Business. Mr. Alecxih brings to TriSalus more than 30 years of experience in product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus' TriNav® Infusion System ("TriNav®"), including device engineering, device quality, sales, marketing, a

    2/21/23 7:00:00 AM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/29/23 8:00:07 AM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/23/23 12:02:13 PM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/22/23 8:15:18 AM ET
    $MTAC
    Medical Specialities
    Health Care